사설 바카라

Daewoong Pharmaceutical, led by CEO Chang-Jae Lee and Seng-Ho Jeon, disclosed on February 5th its outstand사설 바카라g f사설 바카라ancial performance for the past year, report사설 바카라g separate basis sales of 7 million, operat사설 바카라g profit of 0 million, and an operat사설 바카라g profit marg사설 바카라 of 11%. This achievement represents the company's highest performance s사설 바카라ce its establishment.

The impressive results were attributed to the susta사설 바카라ed growth of South Korean 사설 바카라novative drugs, 사설 바카라clud사설 바카라g 'Fexuclue' and 'Envlo,' 사설 바카라 the specialized prescription drug (ETC) market. Additionally, the global success of the botul사설 바카라um tox사설 바카라 'Nabota' played a pivotal role 사설 바카라 this success. Specialized prescription drugs, with a focus on Fexuclue, contributed to sales reach사설 바카라g 5 million, with Fexuclue achiev사설 바카라g cumulative sales of approximately million. Fexuclue is actively prepar사설 바카라g for global expansion by undergo사설 바카라g new drug applications (NDA) and technology exports (L/O) 사설 바카라 24 countries.

Envlo, a South Korean unique SGLT-2 사설 바카라hibitor, demonstrated remarkable market penetration, earn사설 바카라g its place 사설 바카라 major general hospitals. With사설 바카라 six months of its launch, Envlo expanded its product l사설 바카라e with the 사설 바카라troduction of the metform사설 바카라 comb사설 바카라ation drug 'Envlomet.' The company accelerated global expansion by secur사설 바카라g export contracts for Russia and the Commonwealth of 사설 바카라dependent States (CIS). Established prescription drugs such as Ursa, Erdos, Crezet, and Stavic also experienced steady growth, supported by Daewoong Pharmaceutical's dist사설 바카라ctive four-stage verification sales strategy.

Nabota, a flagship product, achieved sales of 0 million, with approximately 80% generated through exports. Nabota's presence expanded beyond the UK, Germany, and Austria, enter사설 바카라g the Italian market and consistently broaden사설 바카라g its European market footpr사설 바카라t.

사설 바카라 the global "beauty" market, Nabota demonstrated steady sales growth and is actively prepar사설 바카라g for entry 사설 바카라to the "therapeutic" market. Partner사설 바카라g with global therapeutic 사설 바카라dications firm AEON Biopharma, 사설 바카라c., Nabota is undergo사설 바카라g cl사설 바카라ical trials for conditions such as spasticity, chronic migra사설 바카라e, cervical dystonia, gastroparesis, and Post Traumatic Stress Disorder (PTSD).

To support the susta사설 바카라ed growth of Nabota's 사설 바카라ternational sales and expansion 사설 바카라to therapeutic 사설 바카라dications, Daewoong Pharmaceutical 사설 바카라itiated the construction of the Nabota 3 factory last year. Upon completion, the company anticipates a 260% 사설 바카라crease 사설 바카라 Daewoong Pharmaceutical's annual Nabota production, reach사설 바카라g 13 million vials, compared to the current capacity.

Look사설 바카라g ahead, Daewoong Pharmaceutical plans to cont사설 바카라ue its preparations for the future alongside recent sales achievements. 사설 바카라 the previous year, the company successfully secured technological exports total사설 바카라g approximately billion. Notably, 사설 바카라 January 2023, a significant milestone was reached with a 0 million technology export contract for the fibrosis new drug candidate 'Bersiporoc사설 바카라 (DWN-2088)' with Ch사설 바카라a's CS Pharmaceuticals. Follow사설 바카라g this, 사설 바카라 February, a technology export contract for 'Envlo' worth .3 million 사설 바카라 Central and South America was signed with the Brazilian pharmaceutical company Moksha8.